Expert Supplier of Deferasirox (CAS 201530-41-8): High Purity Iron Chelator for Pharmaceutical Research
As a leading manufacturer and supplier in China, we offer high-purity Deferasirox (CAS 201530-41-8), a vital oral iron chelator crucial for managing chronic iron overload in patients undergoing long-term blood transfusions. Discover our competitive price and reliable supply.
Get a Quote & SampleUnlock Advanced Pharmaceutical Solutions with Our Deferasirox Supply
Deferasirox (CAS 201530-41-8)
We are a trusted manufacturer and supplier of Deferasirox in China, providing a pharmaceutical-grade iron chelator with ≥99.5% purity. Our reliable supply chain ensures consistent availability, making us your ideal partner for purchasing this critical compound. We offer competitive pricing and excellent customer service.
- High Purity Deferasirox for Pharmaceutical Applications: Essential for treating iron overload, our product meets stringent quality standards.
- Reliable Manufacturer & Supplier in China: Secure your supply chain with a consistent producer of Deferasirox.
- Competitive Price for Bulk Orders: Inquire about our attractive pricing for bulk purchases of Deferasirox.
- Prompt Sample Availability: Request samples to verify the quality and suitability for your research needs.
Advantages of Sourcing Deferasirox from Us
Exceptional Purity and Quality
Our Deferasirox boasts a purity of ≥99.5%, validated by HPLC, making it suitable for demanding pharmaceutical research and applications. Rely on our consistent quality when you buy Deferasirox.
Stable Supply Chain and Production
As a dedicated manufacturer, we ensure a stable and consistent supply of Deferasirox, mitigating risks for your procurement strategy. Our production capacity supports both small and large orders.
Cost-Effective Procurement Solution
We offer competitive pricing for Deferasirox, enabling cost-effective sourcing for your R&D and manufacturing needs. Obtain a quote today for the best price.
Key Applications of Deferasirox
Iron Chelation Therapy
Deferasirox is primarily used to treat chronic iron overload in patients receiving long-term blood transfusions, such as those with thalassemia. It effectively binds and removes excess iron from the body.
Pharmaceutical Research
As a well-characterized compound, Deferasirox is valuable in research settings for studying iron metabolism, cellular signaling, and its potential as an anticancer or antifungal agent.
Treatment of Hemochromatosis
Beyond transfusion-related overload, Deferasirox is indicated for conditions like hemochromatosis and other forms of iron overload, demonstrating its broad therapeutic potential.
Potential Anticancer Agent Research
Research suggests Deferasirox may exhibit anticancer properties by targeting iron-dependent cellular processes, making it an area of active investigation in oncology.